Lead Product(s): TransCon PTH
Therapeutic Area: Endocrinology
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2020
PaTH Forward trial met key objectives and showed that TransCon PTH eliminated standard of care in 82 percent of subjects within four weeks.